Evidence map›Paper›PMID 40649736›Full record

ArticleInternational journal of molecular sciences2025

Overcoming Multidrug Resistance Using DNA-Localized Auger Emitters: A Comparative Analysis of Radiotoxicity in Breast Cancer Cells.

Klaus Schomäcker, Beate Zimmermanns, Thomas Fischer, Markus Dietlein, Ferdinand Sudbrock, Feodor Braun, Felix Dietlein, Melanie von Brandenstein, Alexander Drzezga

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Klaus SchomäckerDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.ORCID 0000-0003-2636-0058
Beate ZimmermannsDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.ORCID 0009-0009-2207-9657
Thomas FischerDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.ORCID 0000-0001-6118-5182
Markus DietleinDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.ORCID 0000-0003-0992-6099
Ferdinand SudbrockDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
Feodor BraunDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
Felix DietleinComputational Health Informatics Program, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-6651-7155
Melanie von BrandensteinDepartment of Urology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50937 Cologne, Germany.
Alexander DrzezgaDepartment of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) represents a major obstacle to successful chemotherapy and, due to overlapping defense mechanisms, such as enhanced DNA repair and the evasion of apoptosis, can also be associated with radioresistance. In this study, we investigated whether MDR breast cancer cells (MCF-7/CMF) exhibit reduced susceptibility to radiation-induced DNA fragmentation compared to their non-resistant parental counterpart (MCF-7). Using a nucleosome-based ELISA, we quantified the chromatin fragmentation in MCF-7 and MCF-7/CMF cells following their exposure to four radiopharmaceuticals: [

Indexed as

Breast NeoplasmsDrug Resistance, MultipleDrug Resistance, NeoplasmRadiopharmaceuticalsCell Line, TumorDNA FragmentationFemaleHumansIodine RadioisotopesMCF-7 CellsIodine RadioisotopesRadiopharmaceuticals[125I]I-iododeoxyuridine (IdU)Auger electron emittersbreast cancer cell linesDNA-targeted radiopharmaceuticalsmultidrug resistance (MDR)

Identifiers

PMID40649736
PMCPMC12250509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.